iOrganBio, a pioneer in intelligent cell manufacturing, today announced the appointment of Lee L. Rubin, Ph.D., to its Scientific Advisory Board. Dr. Rubin, a leading authority in stem cell biology and translational neuroscience, brings decades of expertise in neurodegenerative disease research and therapeutic development to the company's mission of redefining how human cells are engineered and produced at scale.
Dr. Rubin serves as Co-Director and Principal Faculty of the Harvard Stem Cell Institute and Professor in Harvard's Department of Stem Cell and Regenerative Biology. His pioneering work encompasses blood-brain barrier biology, neural stem cell differentiation, disease modeling using patient-derived induced pluripotent stem cells, and the discovery of therapeutic candidates for disorders including Parkinson's disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA).
According to the company, Dr. Rubin's extensive academic and entrepreneurial leadership will be key to expanding iOrganBio's platform in neurological applications. iOrganBio's CellForge platform combines AI prediction, biological sensing, and automated 3D incubation to engineer human cells and organoids with greater precision and consistency, enabling scalable production for disease modeling, drug discovery, and cell therapy development.
This appointment underscores iOrganBio's commitment to advancing FDA-aligned New Approach Methodologies (NAMs) that can reduce reliance on animal testing and accelerate the development of treatments for neurological disorders. Dr. Rubin's expertise in translating stem cell research into therapeutic candidates aligns with the company's goal of providing consistent, high-quality human cells for research and clinical applications.
iOrganBio's CellForge platform uses AI and automation to guide cell development and make real-time adjustments aligned with defined biological profiles. At the core of the platform is iOrganBio's functional human CellAtlas, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type. This closed-loop process aims to deliver the accuracy, efficiency, and quality needed to turn scientific ideas into breakthroughs.
To view the full announcement, including downloadable images and bios, click here.
For more information about iOrganBio and its CellForge platform, visit iOrgan.Bio or follow the company on LinkedIn.
